Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Group One Trading LLC, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Westpark Capital, all published on August 11, 2026.
Last mentioned: Aug 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Group One Trading LLC, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Westpark Capital, all published on August 11, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Westpark Capital. Shared-story counts are live from our verified record — not editorial picks.
Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Source: themarketsdaily.com · dailypolitical.com
Westpark Capital is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
